Being hyped up by the funds of the “quantitative base camp” business department, resulting in abnormal fluctuations in stock tradingPeking University Medicine(000788), released on the evening of the 13thannouncementsevered the relationship with Japan’s Shionogi Pharmaceutical Co., Ltd. of the drug cooperation plan.
Peking University MedicineSaid that the company is concerned about the recent media reports on the progress of the oral drug developed by Shionogi Pharmaceutical Company of Japan to treat the new coronavirus, and the company currently has no plans to cooperate with foreign manufacturers on drugs.
Starting from March,Peking University MedicineThree consecutive daily limits have been closed. From the dismantling point of view, Peking University Pharmaceuticals has risen sharply this round, which is inseparable from the Japanese Shionogi Pharmaceutical Company in terms of news.
At the end of February, Japan’s Shionogi Pharmaceutical Company announced that it had applied to the Japanese Ministry of Health, Labour and Welfare for a production and sales license for oral medicines for the new coronavirus. If admitted, it will be the first Japanese-made oral drug for the new coronavirus to be approved for marketing.
Behind this Japanese pharmaceutical company, the investor comes fromPing AnTie. As the listed platform of Ping An Health, Peking University Pharmaceuticals has a nationwide sales network and a complete production line of APIs. Therefore, it also encountered a frantic hunt for funds in the secondary market.
However, in tonight’s announcement, Peking University Pharmaceuticals also made it clear that the equity transfer and asset delivery of the company’s original actual controllers, Peking University Founder Group Co., Ltd. and Peking University Medical Industry Group Co., Ltd., have not yet been completed.Due to the reorganization of Founder Group, the 2019 and 2020 annual reports of Peking University Pharmaceuticals were issued with qualified audit reports by Tianjian Certified Public Accountants due to the risks of related deposits, related guarantees and overdue accounts receivable from related transactions. There are still uncertainties in the aforementioned risk matters.
This is equivalent to the timely disambiguation of Peking University Pharmaceuticals from drug cooperation plans to equity linkages.
From a broader perspective, because of the optimistic expectations for Japan’s Shionogi Pharmaceutical Company, it is not only Peking University Pharmaceuticals that is supported by funds.
In comparison,Yangtze River HealthThe stock price is more active. In early March this year, some investors asked,Yangtze River HealthWhether there is a cooperative relationship with Chang’ao Pharmaceutical Technology Group, a subsidiary of Japan’s Shionogi Pharmaceutical Co., Ltd.,Yangtze River HealthIn 2020, Hailing Pharmaceutical, a subsidiary of the company, and Chang’ao Group reached a cooperation on the “Lolit” luliconazole cream product.
Recently, the stock price has tended to be activePro Pharma, and also caught the “express train” of Japan’s Shionogi Pharmaceutical Company. On March 9, an investor asked that the company is the supplier of raw materials and intermediates of Shionogi Pharmaceuticals in Japan. I would like to ask whether the company’s products are used in Shionogi-related new crown oral drugs. Puluo Pharma responded that there is a strict confidentiality agreement between the company and CDMO customers, and will not disclose any customer and project-related information.
From the perspective of the secondary market impact, the most obvious impact of Peking University Pharmaceuticals’ drug plan with Shionogi is undoubtedly the funds purchased during the continuous surge in the company’s stock price.
On March 11, Peking University Pharmaceuticals announced theDragon Tiger ListThe data shows that the net purchase of funds is 70.6696 million yuan.From the dismantling point of view, Huaxin, known as the “quantitative base camp”securitiesThe Shanghai branch is listed in the buy one seat, which is known as the “base camp for retail investors”Eastern FortunesecuritiesThe Lhasa business office will sell two seats.
The most noteworthy is HuaxinsecuritiesShanghai Branch.This seat has also recently appeared inLanwei Medicine、Matilda BioThe purchase orders of other diagnostic A-share companies show their optimism about the new crown antigen testing market. However, with the release of Peking University Medicine’s announcement tonight, whether the influx of funds in the past few days can still be safe, it remains to be answered by the stock price performance after the market opens next week.
(Article source: Securities Times e Company)